SurgOnc Today®
SurgOnc Today®
Society of Surgical Oncology
Should Patients at High Risk of Peritoneal Dissemination from Gastric and Colon cancers Undergo HIPEC as an Adjuvant Therapy?
19 minutes Posted Apr 20, 2021 at 5:00 am.
0:00
19:56
Download MP3
Show notes

In this episode, Edward Levine, MD Chair of the SSO Peritoneal Surface Malignancy DSWG, is joined by Brian Badgwell, MD of MD Anderson Cancer Center and Pieter Tanis, MD, PhD of the University of Amsterdam.  They discuss whether patients at high risk of peritoneal dissemination from gastric and colon cancers should undergo HIPEC as an adjuvant therapy.